IDEX

IEX · NYSE

$233.16−$0.70 (−0.30%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $233.86

IEX analyst rating

BuyConsensus of 11 analysts over the last 12 months. 82% rate it a buy.

Strong buy0
Buy9
Hold2
Underperform0
Sell0

12-month price target · 16 analysts

Average $262.82 (+12.7% upside)

Low: $217.15
Now: $233.16
High: $294.00

Upgrades and downgrades

The latest rating actions, newest first

IEX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
RBC Capital	Oct 14, 2026	Maintains	Outperform	$280.00 → $285.00	43%
Oppenheimer	Sep 9, 2026	Maintains	Outperform	$265.00 → $270.00	49%
Mizuho	Aug 12, 2026	Upgrade	Neutral → Outperform	$210.00 → $280.00	66%
DA Davidson	Aug 6, 2026	Maintains	Neutral	$230.00 → $240.00	49%
Argus Research	Aug 6, 2026	Maintains	Buy	$250.00 → $260.00	65%
Citigroup	Jul 30, 2026	Maintains	Buy	$252.00 → $269.00	60%
RBC Capital	Jul 30, 2026	Maintains	Outperform	$261.00 → $280.00	57%
Stifel	Jul 30, 2026	Maintains	Buy	$257.00 → $268.00	61%
TD Cowen	Jul 30, 2026	Maintains	Buy	$260.00 → $275.00	88%
Oppenheimer	Jul 21, 2026	Maintains	Outperform	$250.00 → $260.00	49%

The case for and against

Updated Oct 17, 2026

Bull case

IDEX is benefiting from stronger organic growth across all three segments, led by HST’s exposure to data centers, semiconductors, space/defense, and life sciences, where 2Q26 orders rose 28% year over year and HST orders jumped 47%. The company’s 2026 outlook now implies 5%-6% organic sales growth and adjusted EPS of $8.70-$8.85, supported by productivity gains, IEEPA tariff refund benefits, and improving margins, while free cash flow converted at 103% of net income and net leverage stayed low at 1.3x. Its positive view is further reinforced by a high-quality portfolio, visible backlog through the end of 2026, a $1.1B+ liquidity cushion for accretive buybacks and bolt-on M&A, and growing momentum in high-margin water and industrial end markets.

Bear case

IDEX is facing a negative setup because its short-cycle businesses leave limited visibility, making demand choppiness, tariff-driven pressure, and inventory resets harder to absorb. Although 2Q26 adjusted cash EPS guidance of $2.07-$2.12 and organic sales growth of 3%-4% are solid, adjusted EBITDA margins of 26.5%-27.0% imply a 70 bps year-over-year decline at the midpoint due to tariff timing and higher corporate costs. With shares at 22.4x 2027 P/E and near peers, the valuation looks unexciting given risks from municipal funding volatility, FX, and execution on M&A and growth platforms.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.